<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506542</url>
  </required_header>
  <id_info>
    <org_study_id>not required</org_study_id>
    <nct_id>NCT03506542</nct_id>
  </id_info>
  <brief_title>Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C</brief_title>
  <official_title>Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C Augmented Phacotrabeculectomy: Clinical Results of a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aeon Astron Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Study objective: To assess the efficacy and safety of collagen matrix implant (Ologen®;
           OLO) in phacotrabeculectomy and to compare with mitomycin C (MMC) augmented
           phacotrabeculectomy.

        2. Study Design: The study is designed as a prospective randomized trial. Patient who meet
           the inclusion/exclusion criteria and sign the informed consent form will be included for
           this study.

        3. Follow-Up: This investigation is including 7 post-operative visits and follow-up within
           12 months from the date of surgery. Patients should be seen at postoperative days 1, 7,
           30, 90, 180, 270 and 360.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective randomized comparative study

        -  Patients with cataract and:

      primary open angle glaucoma (POAG) pseudoexfoliation (PEX) glaucoma (PEXG)

        -  Phacotrabeculectomy augmented with OLO or MMC

        -  Follow-up - 12 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2014</start_date>
  <completion_date type="Actual">March 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized and have phacotrabeculectomy augmented with either OLO (Ologen) or MMC (Mitomycin C).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean intraocular pressure (IOP) after the surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease in IOP before and after the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean best corrected visual acuity (BCVA) (LogMAR)</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in best corrected visual acuity (BCVA) (LogMAR) before and after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the filtering bleb in MBGS (Moorfields Bleb Grading System)</measure>
    <time_frame>12 months</time_frame>
    <description>To compare filtrating blebs in two arms of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of antiglaucoma medications</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the number of antiglaucoma medications in two arms of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Glaucoma</condition>
  <condition>Cataract</condition>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Ologen (OLO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin C (MMC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ologen</intervention_name>
    <description>Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C</description>
    <arm_group_label>Ologen (OLO)</arm_group_label>
    <other_name>OLO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacotrabeculectomy</intervention_name>
    <description>Trabeculectomy with cataract extraction</description>
    <arm_group_label>Ologen (OLO)</arm_group_label>
    <arm_group_label>Mitomycin C (MMC)</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)</description>
    <arm_group_label>Mitomycin C (MMC)</arm_group_label>
    <other_name>MMC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cataract

          -  Primary open angle glaucoma or pseudoexfoliation glaucoma with progression of visual
             field loss and/or uncontrolled intraocular pressure levels with medication

        Exclusion Criteria:

          -  Difficulty in reading or speaking Polish

          -  Previous ocular surgery

          -  Pregnant and breastfeeding women

          -  Angle closure glaucoma

          -  Secondary glaucoma except pseudoexfoliation glaucoma

          -  Ocular diseases with excessive scarring

          -  Allergy to collagen or Mitomycin C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Żarnowski, MD PhD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Ophthalmology Clinic, Medical University in Lublin, Poland</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2018</study_first_submitted>
  <study_first_submitted_qc>April 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Aleksandra Wlaz</investigator_full_name>
    <investigator_title>PhD, ophthalmologist in Department of Diagnostics and Microsurgery of Glaucoma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

